visualizations
Patel, Rushang, MD
Overview
overview
- Rushang Patel, MD completed fellowships in bone marrow transplant at Temple University and in hematology/oncology at Fox Chase Cancer Center, one of only 21 prestigious National Comprehensive Cancer Networks (NCCN) in the country. Board-certified in internal medicine and board eligible in medical oncology and hematology, Dr. Patel brings a wealth of clinical knowledge and in-depth research experience to both patient and practice, having worked on projects for United Nations International Children's Emergency Fund (UNICEF), Alembic Pharmaceuticals and Sanofi-Aventis, as well as having conducted studies focused on the mechanisms of cancer formation due to toxic chemicals and identifying new targets for designing cancer drugs
research areas
Affiliation
Member of
-
Clinical Program
-
Research Department
Publications
Most Recent Publications
-
2022Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation. ANNALS OF HEMATOLOGY.Full Text via DOI: 10.1007/s00277-022-05042-z PMID: 36462061
-
2022Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience. INTERNATIONAL JOURNAL OF HEMATOLOGY.Full Text via DOI: 10.1007/s12185-022-03493-8 PMID: 36378406
-
2021Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes. LEUKEMIA RESEARCH. 110.Full Text via DOI: 10.1016/j.leukres.2021.106701 PMID: 34481124
-
2021Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study. TRANSPLANTATION AND CELLULAR THERAPY. 27.Full Text via DOI: 10.1016/j.jtct.2021.04.017 PMID: 33951497
-
2021Impact of Next-Generation Sequencing Cell-free Pathogen DNA Test on Antimicrobial Management in Adults with Hematological Malignancies and Transplant Recipients with Suspected Infections. TRANSPLANTATION AND CELLULAR THERAPY. 27.Full Text via DOI: 10.1016/j.jtct.2021.02.025 PMID: 33849818
-
2020Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. LEUKEMIA & LYMPHOMA. 61:2839-2849.Full Text via DOI: 10.1080/10428194.2020.1789630 PMID: 32650686
-
2020Role of Post-Allogeneic Hematopoietic Stem Cell Transplantation Low-Dose Azacitidine for Prevention of Relapse in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Analysis. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S126-S127.
-
2020Ruxolitinib Is a Safe and Effective Therapeutic Option for Management of Chronic Gvhd - a Single Center Experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S193-S194.
-
2019Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 25:1320-1324.Full Text via DOI: 10.1016/j.bbmt.2019.01.027 PMID: 30710685
-
2019Increased bone marrow CD56(bright) natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome. BONE MARROW TRANSPLANTATION. 924-927.Full Text via DOI: 10.1038/s41409-018-0407-y PMID: 30563982
-
2019Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 19:E93-E97.Full Text via DOI: 10.1016/j.clml.2018.11.007 PMID: 30559058
-
2018Addition of Cladribine: Improving Standard of Care in Newly Diagnosed Acute Myeloid Leukemia. BLOOD.Full Text via DOI: 10.1182/blood-2018-99-120285
-
2018Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation: Case report and review of the literature. TRANSPLANT INFECTIOUS DISEASE.Full Text via DOI: 10.1111/tid.12879 PMID: 29512846
-
2018Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma with P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S253-S254.
-
2018Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S343-S344.
-
2018Post-Transplant Low-Dose Azacitidine Can Improve Overall Survival in AML/MDS Patients and is Associated with Decrease Risks of Severe Acute and Chronic Gvhd. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S327-S327.
-
2018Residual Leukemia in the Bone Marrow and/or Peripheral Blood on Day 7 of Blinatumomab Therapy Predicts Response in B-Cell Acute Lymphoblastic Leukemia. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S237-S237.
-
2018Use of Nitazoxanide, an Anti-Parasitic Drug, for Management of Norovirus Ileo-Colitis in an Allogeneic Stem Cell Transplant Patient. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S394-S395.
-
2017Nivolumab is Effective in Relapsed Refractory Hodgkins Lymphoma Patient Following Mismatched Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S263-S264.
-
2017Sternal Soft Tissue Mass as Initial Presentation in a Case of Acute Promyelocytic Leukemia (APL). BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S208-S208.
-
2017Transverse Myelitis As a Manifestation of Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S310-S310.
-
2016Low Dose Steroids Can Improve High Grade Febrile Episodes Associated with Blinatumomab Therapy and Limit Treatment Interruptions without Affecting Anti Leukemic Effects. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S195-S195.
-
2016Steroid Refractory Acute Liver GVHD in a Hodgkin's Patient after Allogeneic Stem Transplant Cell Transplantation Following Treatment with Anti PD-1 Antibody, Nivolumab, for Relapsed Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S392-S393.
-
2016Thymoglobulin after Matched Unrelated Hematopoietic Stem Cell Transplantation (HCT) in AML/MDS Results in Improved Outcomes Comparable to Matched Related HCT. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S329-S330.
-
2015
Background
Full Name
- Rushang Patel, MD
Education
- Baroda Medical College, Vadodara, Gujarat
Residency
- Abington Memorial Hospital, Abington, PA
Fellowship
- Temple University, Philadelphia, PA
Board Certification
- American Board of Internal Medicine
Contact
primary email
- Research.Institute@AdventHealth.com